Introduction: Primary malignant bone tumors (MBTs) represent about 3% to 5% of cancers in children and less than 1% in adults. Osteosarcoma is the most common, followed by Ewing's sarcoma in children and young adults, and chondrosarcoma in adults. Advances in neoadjuvant chemotherapy and limb-sparing resection techniques have reduced amputations. However, they are still indicated in specific cases, such as unresectable tumors, neurovascular involvement, pathological fractures with contamination, or local recurrence. Objective: To analyze, during the period from 2014 to 2024, the epidemiological profile of lower limb amputations due to malignant bone neoplasms in Brazil. Methods: This is a retrospective, quantitative, and documentary epidemiological study, based on the years 2014 to 2024. The data analyzed came from the System of the Unified Health System (SIH/SUS), provided by the Department of Informatics of the Unified Health System (DataSUS). The variables considered were the number of hospitalizations, type of care (elective/emergency), number of deaths, and the year of the procedures. Results: In the period from 2014 to 2024, 5,145145 hospitalizations for lower limb amputations due to malignant bone neoplasms were recorded in Brazil, of which 3,442 (66%) occurred electively and 1,703 (33%) as emergencies. During the period, there was a 41% increase in the number of annual procedures, from 387 to 541. The Southeast region had the highest volume of cases, totaling 2,463 hospitalizations (49%), followed by the South with 950 hospitalizations (18.5%) and the Northeast with 788 hospitalizations (15%). The lowest rates were observed in the North with 566 hospitalizations (11%) and the Midwest, with 378 hospitalizations (7%). Despite registering a lower absolute number, the North showed the highest proportional growth, with a 72% increase, going from 40 to 69 annual procedures. The Southeast maintained the lead in absolute volume, with a 43% increase (from 182 to 261 procedures). The smallest percentage variation was seen in the Midwest, with a 32% increase, going from 28 to 37 procedures per year. Hospital mortality associated with the procedures totaled 126 deaths (2% of total hospitalizations). The Southeast had the highest absolute number of deaths, totaling 60 cases, while the Midwest had the lowest, with 6 records. Conclusion: The high incidence of emergency hospitalizations reveals inefficiency in the early detection of MBTs, possibly due to the weakening of Primary Health Care and disinformation due to the socioeconomic vulnerability of the Brazilian population. The largest increase in hospitalizations, occurring in the Southeast region, is possibly related to the region’s higher population density and greater investment in Primary Health Units; the first being supported by the higher proportional increase in hospitalizations in the North region, which has the lowest population density in Brazil, and the second, by greater investment in the Southeast’s Primary Health Units. The hospital mortality rate was relatively low, highlighting the prognostic quality of amputation as a treatment for the disease.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
